Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alterity Therapeutics ( (AU:ATH) ) has shared an update.
Alterity Therapeutics announced significant findings from its clinical programs at the 2025 International MSA Congress, highlighting the efficacy of its ATH434 treatment in reducing disease severity and improving symptoms in MSA patients. The introduction of the MSA Atrophy Index as a diagnostic and monitoring tool, along with insights from the bioMUSE study, underscores Alterity’s commitment to advancing MSA treatment and enhancing diagnostic capabilities, potentially impacting patient care and clinical practices.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, with a particular emphasis on Multiple System Atrophy (MSA).
Average Trading Volume: 20,829,623
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$91.27M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.